menu
    • menu
    [{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Provides Clinical Trial Updates for Haduvio\u2122","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lumosa Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lumosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0.01,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Completes Enrollment for Phase 2b\/3 PRISM Study in Chronic Pruritus in PN","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0.059999999999999998,"dosageForm":"Extended-Release Tablet","sponsorNew":"Trevi Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Reports Positive Results from the Ph2b\/3 PRISM Trial of Haduvio\u2122 in the Treatment of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces Pricing of $55 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio\u2122 for Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Nalbuphine Hydrochloride

    Menu

    Nalbuphine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory ...

                            Details : Haduvio (oral nalbuphine ER) is a centrally and peripherally acting investigational therapy which is under phase 2 clinical development for the treatment of refractory chronic cough (RCC).

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : SVB Securities

                            Deal Size : $55.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Announces Pricing of $55 Million Public Offering

                            Details : The company will use the net proceeds from the offering for the development of clinical pipeline including its lead product Haduvio (nalbuphine) and for other general and corporate purpose.

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 23, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : SVB Securities

                            Deal Size : $55.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Co...

                            Details : Primary efficacy endpoint demonstrated 77.3% reduction in daytime cough frequency from baseline with use of Haduvio (nalbuphine ER) compared to 25.7% reduction with placebo, 52% placebo-adjusted reduction in geometric mean percent change in daytime cough...

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prur...

                            Details : Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157).

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Frazier Life Sciences

                            Deal Size : $55.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

                            Details : Company intends to use net proceeds from the private placement for the clinical development of Haduvio (Nalbuphine ER), a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist for chronic cough in IPF and working capital and other general co...

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Frazier Life Sciences

                            Deal Size : $55.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

                            Details : The primary efficacy endpoint demonstrated a 77.3% reduction in daytime cough frequency from baseline with use of Haduvio compared to a 25.7% reduction with placebo, demonstrating a 52% placebo-adjusted reduction in geometric mean percent change in dayt...

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Na...

                            Details : Interim analysis showed primary efficacy endpoint of cough reduction was highly statistically significant (p<0.0001) for Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept.

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

                            Details : Phase 2b/3 PRISM trial enrollment completed for Haduvio (nalbuphine ER), mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist for the treatment of pruritus associated with prurigo nodularis.

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2022

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Trevi Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Stifel

                            Deal Size : $11.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

                            Details : The Company will use the net proceeds from the private placement for the development of an investigational therapy Haduvio™, an oral extended-release (ER) formulation of nalbuphine to treat serious neurologically mediated conditions.

                            Brand Name : Haduvio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 30, 2021

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Stifel

                            Deal Size : $11.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lumosa Therapeutics

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed

                            Lumosa Therapeutics

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's ...

                            Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.

                            Brand Name : LT1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2020

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4